Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
DONEPEZIL HYDROCHLORIDE
PCO Manufacturing
DONEPEZIL HYDROCHLORIDE
5 Milligram
Film Coated Tablet
Product subject to prescription which may not be renewed (A)
Authorised
0000-00-00
* Glossary [/homepage/site-tools/glossary] * As Gaeilge [/irish-homepage] [The Health Products Regulatory Authority logo] [/../../../../leaflets] My HPRA: Login [/../../../login] Register [/../../../register] * About Us [/../../about-us] * Medicines [/../../medicines] * Veterinary [/../../veterinary] * Medical Devices [/../../medical-devices] * Blood, Tissues, Organs [/../../blood-tissues-organs] * Cosmetics [/../../cosmetics] * Controlled Substances [/../../controlled-substances] * Glossary [/../glossary] * Copyright [/../copyright] * Privacy [/../privacy] * Contacts [/../homepage-about-us-contact-us] * Links [/../links] * Disclaimer [/../disclaimer] * Sitemap [/../sitemap] * Cookie Policy [/../cookie-policy] * Search [/../search] OOPS SOMETHING WENT WRONG! Apologies but something has gone wrong. Please use our search facility above or the navigation to continue. ABOUT US [/../../about-us] * How We Regulate [/../../about-us/how-we-regulate] * Our New Name [/../../about-us/our-new-name-and-brand] * Contact Us [/../../about-us/contact-us] * Our Structure [/../../about-us/our-structure] * Standards of Service [/../../about-us/standards-of-service] * Information and Transparency [/../../about-us/information-transparency] * Quality Management [/../../about-us/quality-management] * Recruitment [/../../about-us/recruitment] * Publications & Forms [/../../about-us/publications-forms] * Report an Issue [/../../about-us/report-an-issue] * Legislation [/../../about-us/legislation] * Extranets [/../../about-us/extranets] MEDICINES [/../../medicines] * Our Role [/../../medicines/our-role] * Medicines Information [/../../medicines/medicines-information] * Safety Information [/../../medicines/safety-information] * Safety Notices [/../../medicines/safety-notices] * Quality Information [/../../medicines/quality-information] * Regulatory Information [/../../medicines/regulatory-information] * News & Events [/../../medicines/news-events] * Special Topics [/../../medicines/special-topics] VETERINARY [/../../veterinary] * Our Role [ Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT ARICEPT 5 mg film coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg donepezil hydrochloride. Excipient with known effect: lactose monohydrate For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet _Product imported from France, Greece and Spain:_ White, round, biconvex tablets with ‘ARICEPT’ on one side and ‘5’ on the other side. _Product imported from Italy:_ White, round, biconvex tablets with ‘ARICEPT’ on one side and ‘5’ on the other side OR white, round, biconvex tablets with no markings. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ARICEPT tablets are indicated for the symptomatic treatment of mild to moderately severe Alzheimer’s dementia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults/Elderly: Treatment is initiated at 5 mg/day (once-a-day dosing). ARICEPT should be taken orally, in the evening, just prior to retiring. The 5 mg/day dose should be maintained for at least one month in order to allow the earliest clinical responses to treatment to be assessed and to allow steady-state concentrations of donepezil hydrochloride to be achieved. Following a one-month clinical assessment of treatment at 5 mg/day, the dose of ARICEPT can be increased to 10 mg/day (once-a-day dosing). The maximum recommended daily dose is 10 mg. Doses greater than 10 mg/day have not been studied in clinical trials. Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia. Diagnosis should be made according to accepted guidelines (e.g. DSM IV, ICD 10). Therapy with donepezil should only be started if a caregiver is available who will regularly monitor drug intake Read the complete document